Replimune stock.

Today's High Today's Low 52 Week High 52 Week Low FL Technical Analysis Tools & Settings Open High Low Close Volume Volume remove 1DY | 5DY | | 3M | | YTD | | | | Max |

Replimune stock. Things To Know About Replimune stock.

Replimune has assembled a world-class leadership team who together pioneered the development of the first and only FDA-approved oncolytic immunotherapy. Supported by renowned scientists, clinicians, and advisors, we are working to advance the field by developing optimally designed tumor-directed oncolytic immunotherapies to treat a broad …15 Okt 2020 ... Replimune stock rallied on leaked RP1 and RP2 clinical trial data. Its cash position enables it to invest more in clinical studies.Replimune Group Inc (REPL) Stock Price Today, Quote, Latest Discussions, Interactive Chart and News DIA 0.02% 5.71% GST.X 26.01% SKL.X 34.16% KAS.X 1.70% KDA.X …Complete Replimune Group Inc. stock information by Barron's. View real-time REPL stock price and news, along with industry-best analysis.If you are looking for stocks with good return, Replimune Group Inc stock can be a bad, high-risk 1-year investment option. Replimune Group Inc real time quote is equal to 10.390 USD at 2023-11-25, but your current investment may be devalued in the future.

Replimune remains on track to initiate its Phase 2 development program with RP2/3 in the first half of 2023. As previously announced, this program is intended to include Phase 2 clinical trials in ...Is Replimune Stock a Buy? The Bottom Line. Replimune has a lot of potential to treat melanomas and other cancerous tumors. If it's proven effective, it can ...WOBURN, Mass.Nov. 23, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic ...

37 Salaries (for 31 job titles) • Updated Oct 29, 2023. How much do Replimune employees make? Glassdoor provides our best prediction for total pay in today's job market, along with other types of pay like cash bonuses, stock bonuses, profit sharing, sales commissions, and tips. Our model gets smarter over time as more people …Dec 9, 2022 · In addition, in lieu of common stock to certain investors, Replimune today announced the pricing of its public offering of pre-funded warrants to purchase 4,200,000 shares of its common stock at a purchase price of $23.4999 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.0001 per share ...

Complete Replimune Group Inc. stock information by Barron's. View real-time REPL stock price and news, along with industry-best analysis.Replimune story: Exercise or conversion by Pamela Esposito of 25800 shares of Replimune subject to Rule 16b 3 and other headlines for Replimune GroupReplimune remains on track to initiate its Phase 2 development program with RP2/3 in the first half of 2023. As previously announced, this program is intended to include Phase 2 clinical trials in ...BOSTON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced the pricing of its public offering of 5,374,486 shares of its common stock at a public offering price of …S-3 1 tm2027068-1_s3.htm FORM S-3 ...

PURPOSE We evaluated the activity of intratumoral Coxsackievirus A21 (V937) in 57 patients with unresectable stage IIIC or IV melanoma. PATIENTS AND METHODS In this multicenter, open-label, phase II study, patients received up to a total V937 dose of 3 × 108 TCID50 (50% tissue culture infectious dose) in a maximum 4.0-mL …

On­colyt­ic virus ex­perts at Replimune re­load with $200M loan as biotech col­lects clin­i­cal da­ta ... cal plans from rak­ing in the cash — ei­ther through stock of­fer­ings or ...

Dec 9, 2022 · In addition, Replimune has granted the underwriters a 30-day option to purchase up to an additional 1,436,172 shares of its common stock from Replimune at the public offering price, less the ... Nov 30, 2023 · Replimune Group stock has received a consensus rating of buy. The average rating score is and is based on 21 buy ratings, 0 hold ratings, and 0 sell ratings. What was the 52-week low for Replimune ... We conduct our clinical trials with the highest possible standards. Replimune is also closely monitoring the ongoing COVID-19 pandemic to ensure patient safety. To download and learn more detailed information about Oncolytic Immunotherapy and RP1, click here. You can find more information about our ongoing clinical trials below.The average price recommended by analysts for Replimune Group Inc is $48.44, which is significantly higher than the current market price. This suggests that there is room for the stock price to increase, according to analysts’ predictions. The company has also been involved in the development of a treatment for cutaneous squamous cell ...Nov 24, 2023 · According to the issued ratings of 6 analysts in the last year, the consensus rating for Replimune Group stock is Buy based on the current 6 buy ratings for REPL. The average twelve-month price prediction for Replimune Group is $51.33 with a high price target of $70.00 and a low price target of $34.00. Learn more on REPL's analyst rating history. Stock control is important because it prevents retailers from running out of products, according to the Houston Chronicle. Stock control also helps retailers keep track of goods that may have been lost or stolen.Replimune story: Exercise or conversion by Pamela Esposito of 25800 shares of Replimune subject to Rule 16b 3 and other headlines for Replimune Group

WOBURN, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced updated interim results from ARTACUS, a Phase 1/2 clinical trial evaluating RP1 monotherapy for the treatment of skin cancers in patients who have had solid organ or ...Complete Replimune Group Inc. stock information by Barron's. View real-time REPL stock price and news, along with industry-best analysis. Replimune story: Exercise or conversion by Pamela Esposito of 25800 shares of Replimune subject to Rule 16b 3 and other headlines for Replimune GroupReplimune Group Stock Performance. Shares of REPL stock opened at $11.71 on Monday. The company has a market cap of $691.58 million, a price-to-earnings ratio of -3.80 and a beta of 1.46. The stock has a 50 day simple moving average of $13.43 and a 200-day simple moving average of $18.08.Dec 9, 2022 · In addition, Replimune has granted the underwriters a 30-day option to purchase up to an additional 1,436,172 shares of its common stock from Replimune at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on December 13, 2022, subject to the satisfaction of customary closing conditions.

Since its IPO on the Shenzhen stock exchange, its share price has gone up every day by the exact same amount. Baofeng Technologies is China’s best performing stock this year. Since its IPO on the Shenzhen stock exchange, its share price has...

Dec 1, 2023 · View Replimune Group, Inc REPL investment & stock information. Get the latest Replimune Group, Inc REPL detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Replimune overview. Replimune, a subsidiary of Replimune Group Inc, is a pharmaceutical company that develops oncolytic immunotherapies for the treatment of cancer. The company’s pipeline products include RP1 used for the treatment of oncolytic immunotherapy backbone, and RP2 and RP3 for expressing anti-CTLA-4 and co …A high-level overview of Replimune Group, Inc. (REPL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.The Replimune Group Inc. stock price fell by -1.34% on the last day (Wednesday, 22nd Nov 2023) from $10.43 to $10.29. During the last trading day the stock fluctuated 4.10% from a day low at $10.25 to a day high of $10.67. The price has fallen in 7 of the last 10 days and is down by -10.83% for this period.WOBURN, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed ...Jul 9, 2023 · Replimune's RPx platform, featuring RP1, RP2, and RP3, showcases a comprehensive and innovative approach to cancer treatment. Find out why REPL stock is a Buy. Are you tired of spending endless hours searching for high-quality stock photos only to discover that they come with a hefty price tag? Look no further. In this article, we will explore the best sources for high-quality really free stock ph...Dec 4, 2023 · Replimune Group Stock Performance. Shares of REPL stock opened at $11.71 on Monday. The company has a market cap of $691.58 million, a price-to-earnings ratio of -3.80 and a beta of 1.46. The stock has a 50 day simple moving average of $13.43 and a 200-day simple moving average of $18.08.

Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immuno-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune …

Jul 9, 2023 · Replimune's RPx platform, featuring RP1, RP2, and RP3, showcases a comprehensive and innovative approach to cancer treatment. Find out why REPL stock is a Buy.

Replimune will grant to Mr. Patel a nonqualified stock option to purchase up to 125,000 shares of Replimune’s common stock, $0.001 par value per share (“Common Stock”), on the date he commences employment, at a purchase price per share equal to the closing price per share of Common Stock on the Nasdaq Global Select Market on such date.Replimune Group, Inc. (REPL) stock forecast and price target. Find the latest Replimune Group, Inc. REPL analyst stock forecast, price target, and recommendation trends with in-depth analysis from ...About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the ...Christopher Sarchi REPL stock SEC Form 4 insiders trading. Christopher has made over 1 trades of the Replimune Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Christopher sold 5,255 units of REPL stock worth $57,385 on 16 November 2023.. The largest trade Christopher's ever made was selling 5,255 …The stock of Replimune Group Inc (REPL) has gone up by 13.26% for the week, with a -15.10% drop in the past month and a -44.22% drop in the past quarter. The volatility ratio for the week is 7.61%, and the volatility levels for the past 30 days are 9.26% for REPL. The simple moving […]The inducement awards consist of a non-qualified stock option to purchase 82,500 shares of the Company’s common stock and restricted stock units representing 55,000 shares of the Company’s common stock. The option has an exercise of $27.20 per share, which is equal to the closing price of the Company’s common stock on the date of grant ...Complete Replimune Group Inc. stock information by Barron's. View real-time REPL stock price and news, along with industry-best analysis.Replimune Group, Inc. ( NASDAQ:REPL – Get Free Report) shares were down 3.4% during trading on Friday . The company traded as low as $10.80 and last traded at $10.80. Approximately 15,578 shares traded hands during trading, a decline of 97% from the average daily volume of 618,826 shares. The stock had previously closed at $11.18.Earnings Summary. For their last quarter, Replimune Group (REPL) reported earnings of -$0.90 per share, missing the Zacks Consensus Estimate of -$0.80 per share. This reflects a negative earnings ...Aug 8, 2023 at 1:30 PM EDT. Jefferies Global Healthcare Conference. Jun 8, 2023 at 1:00 PM EDT. Piper Sandler Spring Biopharma Symposium. May 17 - May 18, 2023. Jefferies Biotech on the Bay Summit. Mar 16, 2023. Barclays Global Healthcare Conference. Mar 15, 2023 at 2:05 PM EDT.

The Replimune Group Inc. stock price fell by -1.82% on the last day (Wednesday, 29th Nov 2023) from $11.53 to $11.32.During the last trading day the stock fluctuated 6.13% from a day low at $11.26 to a day high of $11.95.The price has been going up and down for this period, and there has been a 0.89% gain for the last 2 weeks.Contact Email: [email protected]. Contact Phone Number: +1 (781) 222 9570. Replimune’s investigational products and their uses are investigational, have not been proven to be safe and have not been approved by the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA) or any other regulatory authority. Discover historical prices for REPL stock on Yahoo Finance. View daily, weekly or monthly format back to when Replimune Group, Inc. stock was issued.Replimune ends selloff after FDA response to mid-stage cancer trial. Following four straight sessions of losses, oncology-focused biotech Replimune Group ( NASDAQ: REPL) added ~7% on Monday after ...Instagram:https://instagram. employer match calculatoriner stockday trading programgempharmatech Get Replimune Group Inc (REPL.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments best day to buy stockworkers comp companies in california In other Replimune Group news, insider Pamela Esposito sold 5,358 shares of the business’s stock in a transaction on Monday, September 11th. The shares were sold at an average price of $20.01 ...Cannabis Stocks. 164.71k followers • 21 symbols +0.34% Watchlist by Yahoo Finance. Follow this list to discover and track the stock of publicly traded companies with exposure to cannabis. expedia shares Nov 7, 2023 · About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the ... Replimune Group, Inc. (REPL) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M 11.71 +0.53 (+4.74%) At close: 04:00PM EST 11.71 0.00 (0.00%) After hours: 04:20PM EST 1d 5d 1m...